Prevention and control of Ebola virus infection

$558,116U54FY2010AINIH

University Of Chicago, Chicago IL

Investigators

Linked publications & trials

Paper 32574901 Paper 31534221 Paper 31405862 Paper 31324436 Paper 29632532 Paper 29520087 Paper 28781126 Paper 28698584 Paper 28674069 Paper 28512097 Paper 28325762 Paper 27547819 Paper 27234592 Paper 27226531 Paper 27199935 Paper 27129288 Paper 26880271 Paper 26831700 Paper 26519448 Paper 26458291 Paper 26305782 Paper 26305471 Paper 26192200 Paper 26137737 Paper 26091171 Paper 26067604 Paper 25987613 Paper 25937339 Paper 25927232 Paper 25814063 Paper 25779326 Paper 25759502 Paper 25701232 Paper 25550354 Paper 25505855 Paper 25462353 Paper 25457179 Paper 25367569 Paper 25362065 Paper 25359083 Paper 25239905 Paper 25230938 Paper 25183728 Paper 25073644 Paper 25040808 Paper 24975990 Paper 24958706 Paper 24922575 Paper 24914184 Paper 24867981 Paper 24866799 Paper 24838262 Paper 24820433 Paper 24799624 Paper 24799499 Paper 24783062 Paper 24769066 Paper 24753256 Paper 24748386 Paper 24740631 Paper 24627965 Paper 24573681 Paper 24567418 Paper 24550724 Paper 24532772 Paper 24510849 Paper 24490592 Paper 24481289 Paper 24478100 Paper 24476714 Paper 24449899 Paper 24443700 Paper 24434550 Paper 24415755 Paper 24415723 Paper 24401083 Paper 24391055 Paper 24386389 Paper 24366742 Paper 24363342 Paper 24357631 Paper 24349254 Paper 24339776 Paper 24331465 Paper 24297496 Paper 24291195 Paper 24284176 Paper 24269844 Paper 24251537 Paper 24233725 Paper 24167300 Paper 24158443 Paper 24136289 Paper 24134710 Paper 24123823 Paper 24106961 Paper 24049163 Paper 24034615 Paper 23982075 Paper 23970550

Abstract

Our long-term goal is to develop vaccines and antiviral treatments for Ebolavirus infections. We have developed biologically contained Ebolaviruses that protect mice against challenge with a lethal dose of mouse-adapted Ebolavirus. In Aim 1, we plan to test the protective efficacy of these Ebolaviruses in guinea pigs and nonhuman primates. Towards drug development, we have established three different highthroughput screening systems that allow screening in BSL-2 containment. In Aim 2, we propose to conduct high-throughput screening and to optimize lead compounds. The lack of effective preventive or therapeutic treatments for Ebolavirus infections is partly due to the lack of knowledge of cellular genes involved in Ebolavirus replication. Our pilot study demonstrated the potential of siRNA screening approaches to identify such genes;therefore, we plan to conduct siRNA screening of commercially available human siRNA libraries to identify critical genes for the Ebolavirus life cycle (Aim 3). Candidate genes/gene products will then be characterized to elucidate the mechanism(s) by which they interfere with Ebolavirus replication. Studies in Aim 3 may thus suggest novel approaches to the treatment of Ebolavirus infections.

View original record on NIH RePORTER →